Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

• Main Authors: Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R.
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2019
• Subjects: NAFLD; Science::Medicine; Dual‐PPAR Agonist
• Online Access: https://hdl.handle.net/10356/106322; http://hdl.handle.net/10220/49606
• Institution: Nanyang Technological University

Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH....